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ABSTRACT
Adjuvant therapy has made a significant contribu-
tion in reducing breast cancer–specific mortality.
Standard chemotherapeutics and tamoxifen have been
the mainstay treatment for years, but recent clinical
evidence supports the use of novel small-molecule
therapy and aromatase inhibitor therapy in selected
settings, challenging not only the traditional paradigm
of breast cancer treatment, but also provincial fund-
ing of oncologic care across Canada. The disparity
in access to aromatase inhibitor therapy for postmeno-
pausal women with early-stage hormone-sensitive
breast cancer across Canada is highlighted as an
example.
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1. INTRODUCTION
The aim of the Canada Health Act is to ensure that
all eligible Canadian residents have reasonable ac-
cess to publicly funded health care. The federal leg-
islation requires comprehensive and universal access
to publicly insured hospital, medical, and surgical–
dental services uniformly, without any discrimina-
tion with regard to age, health status, or additional
financial burden.
Innovative cancer therapies and advances in drug
development have created new hope for patients and
their health providers, but also contribute to an in-
crease in health expenditures in an already cost-con-
scious environment 1. A case in point is the aromatase
inhibitors (AIs), which are recommended as adjuvant
therapy to lower the risk of tumour recurrence for
postmenopausal women with early-stage hormone-
dependent breast cancer. With cost-containment ef-
forts being a major focus of all payers in Canada,
widespread disparity in drug reimbursement exists
among the provinces, cancer agencies, and hospitals.
In terms of the enormity of the health care issue,
the statistics speak for themselves. One of every nine
Canadian women is expected to develop breast can-
cer in her lifetime, and 1 of every 27 women is ex-
pected to die from breast cancer. As reported by the
Canadian Cancer Society and the National Cancer
Institute of Canada in Canadian Cancer Statistics
2007, an estimated 22,300 Canadian women will be
diagnosed with breast cancer in 2007 and 5300 will
die secondary to breast cancer (Table I), making this
disease the most common cancer in women and the
second leading cause of cancer mortality 2.
Mammographic screening and adjuvant therapies
following breast cancer surgery have helped to con-
tribute to a decline in annual mortality (1.2% per year
since 1999) 2 ; however, despite a declining incidence
of breast cancer in Canada in recent years, the cur-
rent incidence of 104 cases per 100,000 (29% of all
cancers) is still among the highest in the world ac-
cording to the report, and the largest number of new
cases occur in women between the ages of 50 and
59 years. In fact, breast cancer is the most common
cancer in women under 50 years of age, in those 50
to 69 years of age, and in those 70 years of age and
older, and it is the most common cause of cancer death
in women under 50 years of age 2. In view of these
high incidence and mortality rates, the need for
prompt and early intervention with the most effica-
cious therapeutic regimen cannot be overstated 2.
Adjuvant therapy (local radiation or systemic
treatment given after surgical resection for early-stage
disease) for breast cancer was first used more than
100 years ago, but really moved forward following
the discovery by Jensen and Jacobson of estrogen
receptor action in the early 1960s 3. Approximately
two thirds of postmenopausal breast cancer cases are
estrogen-dependent 4–6, and through years of research,
selective estrogen receptor modulators such as tamox-
ifen have become a cornerstone of treatment, reduc-
ing breast cancer recurrence and overall mortality in
early-stage disease 7.
But treatment success has come at the cost of
potential drug-related side effects—for example, the
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risk of thromboembolic disease and of endometrial
cancers associated with the partial estrogen agonist
effect of tamoxifen. Potent AIs 8,9 were developed for
complete estrogen blockade in postmenopausal
women (by inhibiting the cytochrome P450 aromatase
complex that converts peripheral androgens to estra-
diol), and compared with tamoxifen, they have dem-
onstrated greater efficacy and a favourable side effect
profile in both early- and late-stage hormone recep-
tor–positive breast cancer 10–12.
Current key international guidelines support the
use of these third-generation AIs for the treatment of
early breast cancer in postmenopausal women with
hormone receptor–positive disease. The American
Society of Clinical Oncology Technology Assessment
Panel, the St. Gallen expert consensus, and the U.K.
National Institute for Health and Clinical Excellence
all recommend AIs to lower the risk of tumour recur-
rence for postmenopausal women with early-stage
hormone receptor–positive breast cancer 13–15. Strat-
egies such as “upfront” AI therapy (substituting for
5 years’ tamoxifen therapy), or following tamoxifen
therapy as an “early switch” (after 2–3 years of
tamoxifen therapy) or as “extended adjuvant” therapy
(after 5 years of adjuvant tamoxifen therapy) are cur-
rently supported.
2. EFFICACY OF UPFRONT AIs
Initial adjuvant therapy with an AI has been compared
with tamoxifen in the Arimidex, Tamoxifen Alone,
or in Combination (ATAC) trial (anastrozole) and in
the Breast International Group (BIG) 1-98 (letrozole)
trial 16–19.
In ATAC, disease-free survival was higher in the anas-
trozole group at 33, 47, and 68 months (Table II) 16–20.
Benefits for the anastrozole group in terms of disease-
free survival, time to recurrence, contralateral incidence,
and time to distant recurrence persisted even after
5.7 years of follow up. Overall survival was similar
between the two groups [hazard ratio (HR): 0.97; 95%
confidence interval (CI): 0.85 to 1.12; p = 0.7] 16.
Similar results were obtained from an updated
analysis of the BIG 1-98 monotherapy arms at a me-
dian follow-up of 51 months, confirming published
evidence 19 that letrozole monotherapy is superior to
tamoxifen in the defined primary endpoint of disease-
free survival (84.0% vs. 81.1%, p = 0.007), and in the
secondary endpoint of time to distant recurrence
(Table III; Coates AS. Letrozole versus tamoxifen:
update of continuous therapy arms of BIG 1-98. Pre-
sented at the XXth Congress of the European Society
for Medical Oncology; Istanbul, Turkey; Septem-
ber 29–October 3, 2006). At a median follow-up of
51 months, 352 disease-free survival events were seen
among 2463 women receiving letrozole and 418 events
among 2459 women receiving tamoxifen, reflecting
an 18% reduction in the risk of an event (HR: 0.82;
95% CI: 0.71 to 0.95; p = 0.007) 21.
3. EFFICACY OF “SWITCH” AND “EXTENDED
ADJUVANT” AI TRIALS
The results of the Intergroup Exemestane Study (IES)
trial, the Austrian Breast and Colorectal Cancer Study
Group (ABCSG) 8 trial, the Arimidex–Novaldex (ARNO)
trial, and the smaller Italian Tamoxifen Anastrozole
(ITA) trial all demonstrated the benefit of switching
patients to an AI after 2–3 years of tamoxifen therapy.
That switch significantly improved disease-free sur-
vival (local or metastatic recurrence, contralateral
breast cancer, or death from any cause) as compared
with standard adjuvant tamoxifen therapy
(Table  IV) 22–25. In addition, a modest improvement in
overall survival was noted, with 222 deaths occurring
in the exemestane group as compared with 261 deaths
in the tamoxifen group (HR: 0.83; 95% CI: 0.69 to 1.00;
p = 0.05) after 122 patients with estrogen receptor–
negative disease had been excluded 26.
Regardless of nodal status, extended adjuvant
therapy may be warranted for patients completing
about 5 years of tamoxifen therapy in view of contin-
ued risk of recurrence 27. In this regard, the final analy-
sis of the results from the National Cancer Institute of
TABLE I Estimates for female breast cancer in Canada, 2007 2
Province Age-standardized New cases Deaths Age-standardized
incidence rates mortality rates
(per 100,000) (per 100,000)
Newfoundland and Labrador 101 370 100 27
Prince Edward Island 111 110 25 27
Nova Scotia 101 680 200 27
New Brunswick 100 540 130 23
Quebec 111 5900 1400 24
Ontario 104 8500 2000 23
Manitoba 107 810 210 25
Saskatchewan 98 630 150 22
Alberta 106 2000 440 22
British Columbia 93 2700 640 20VERMA et al.
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Canada Clinical Trials Group MA.17 study confirmed
that letrozole significantly reduces the risk of relapse,
including distant metastases, as compared with pla-
cebo in women who remained disease-free for up to
3 months after completion of tamoxifen treatment. In
addition, overall survival improved significantly in
patients with node-positive disease at diagnosis 28.
4. SIDE EFFECTS OF AI THERAPY
In general, tamoxifen may have a role in patients with
low risk of recurrence or poor tolerance for AIs, but
the use of third-generation AIs is superior to tamoxi-
fen in terms of certain toxicity profiles 29. The AIs have
a lower incidence of thromboembolic events and vagi-
nal bleeding as compared with tamoxifen, and they
do not increase the risk of endometrial neoplasia (and
indeed may possibly be protective). Their impact on
bone turnover and lipid metabolism varies with their
individual safety profiles 30. Increased rates of arthral-
gia and myalgia are also seen with the AIs.
5. THE CANADIAN SCENARIO
According to an online survey of 454 Canadian
oncologists across 10 provinces, upfront adjuvant
therapy with an AI is preferred for at least 50% of pa-
tients with postmenopausal estrogen receptor–positive
early breast cancer 31. However, access to AI treatment
strategies varies widely by province (Tables V, VI, VII).
TABLE IV Disease-free survival with aromatase inhibitors in sequential strategies
Trial Treatment protocol Follow-up HR 95% CI p Value Absolute risk Years from
(months) reduction (%) randomization
IES 22,23 Switch to exemestane 31 0.68 0.56 to 0.82 <0.001 4.7 3
(n=2362) after 2–3 years
ABCSG-8/ Anastrozole treatment 28 0.60 0.44 to 0.81 0.0009 3.1 3
ARNO 24 after 2 years
ITA 25 Switch to anastrozole 36 0.35 0.18 to 0.68 0.001 5.8 3
at 2 years
IES = Intergroup Exemestane Study; ABCSG-8/ARNO = Austrian Breast and Colorectal Cancer Study Group-8 trial and the Arimidex–Novaldex
trials; ITA = Italian Tamoxifen Anastrozole trial.
TABLE III Updated analysis of the Breast International Group (BIG) collaborative study 1-98 data
Median follow-up
26 Months (BIG 2005 19) 51 Months (Coates 2006 a)
Letrozole Tamoxifen Letrozole Tamoxifen
Patients (N) 4003 4007 2463 2459
Disease-free survival events 351 428 352 418
Systemic disease-free survival events 323 383 331 374
Deaths 166 192 194 211
a Coates AS. Letrozole versus tamoxifen: update of continuous therapy arms of BIG 1-98. Presented at the XXth Congress of the European
Society for Medical Oncology; Istanbul, Turkey; September 29–October 3, 2006.
TABLE II Disease-free survival in the Arimidex, a Tamoxifen, Alone or in Combination trial, patients with hormone receptor–posi-
tive tumours 20
Comparison Follow-up
33 Months 17 47 Months 18 68 Months 16
HR b 95% CI p Value HR b 95% CI p Value HR b 95% CI p Value
Anastrozole vs. tamoxifen 0.78 0.65 to 0.93 0.003 0.82 0.70 to 0.96 0.014 0.83 0.73 to 0.94 0.005
Anastrozole vs. combination 0.76 0.63 to 0.91 0.002 NR Combination therapy
discontinued
a AstraZeneca Canada, Mississauga, ON (generic name: anastrozole).
b Hazard ratios shown in bold type are statistically significant.
HR = hazard ratio; CI = confidence interval; NR = not reported.CANCER THERAPY DISPARITY
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5.1 Challenges with Reimbursement Strategies in
Canada
Although the year 2006 saw a major breakthrough,
with $260 million in federal funding for the Cana-
dian Partnership Against Cancer 32, access to highly
effective new drugs remains a major challenge for
cancer patients. As health agencies review guidelines
to define eligibility for treatment with AIs, funding
issues remain disparate and unresolved. Increasingly,
the trend has been toward self-pay or third-party re-
imbursement by publicly funded cancer centres.
Currently, cancer reimbursement in Canada is
managed provincially by agencies that create guide-
lines for drug usage aimed at standardizing patient
care and cost expenditure, but also by provincial can-
cer programs and individual hospitals. A broad tar-
get patient population is the key rationale underlying
drug reimbursement strategy, usually determined by
a scientific process and review by disease-site groups.
TABLE VI Disparities in Canadian drug reimbursement guidelines for aromatase inhibitors (AIs)
Quebec No standard provincial guidelines
Hospital pharmacy and therapeutics committees decide chemotherapy usage with formulary listing
Régie de l’assurance maladie du Québec covers oral and intravenous chemotherapies
Seniors 65 years of age and older have the choice of exclusive third-party insurance, if required, with open,
unrestricted coverage for AIs and tamoxifen
Ontario Cancer Care Ontario Clinical Practice Guideline or Evidence Summary used for reimbursement decisions on
anticancer agents, reviewed by multidisciplinary Disease Site Groups
AIs are associated with some limited-use criteria in Ontario Drug Benefit program
Ontario Drug Benefit covers seniors over 65 years of age, residents of long-term care facilities and Homes for
Special Care, recipients of professional services under home care, and people on social assistance
Trillium Drug Program covers those ineligible under Ontario Drug Benefit and lacking private insurance; requires
patient deductibles and co-pays
Third-party insurers also cover oral and hormonal therapies, supportive care outpatient treatments
Saskatchewan Restricted public coverage of AIs
Manitoba Manitoba’s Pharmacare Program reimburses AI therapies once patient deductibles are met
British Columbia Public-sector reimbursement of AIs restricted, interchangeable, and based on prognostic factors
Upfront therapy with an AI for women with an elevated risk of early relapse, defined as high grade or low estrogen
receptor (1+) disease or stage III (including any N2/N3, T4, or T3N+) and excludes women with low-grade T1N0
tumours
Sequential therapy is preferred for most postmenopausal women who are not at high risk for early relapse:
Early switch to an AI for 2–3 years after 2–3 years of tamoxifen
Late switch to an AI for 3 years after 3–5 years of tamoxifen, or if postmenopausal after 3 years of tamoxifen
Atlantic Canada No specific guidelines on AI use
Second-line AI therapy for patients who have failed, are intolerant of, or have an absolute contraindication to
tamoxifen (with the exception of Nova Scotia)
TABLE V Public access to adjuvant endocrine therapy across Canada, as at July 2007
Tamoxifen Anastrozole Letrozole Exemestane
Ontario Open Limited use Limited use Limited use
Québec Open Open Open Open
Alberta Open Restricted Restricted Restricted
British Columbia Open Restricted Restricted Restricted
(based on (based on (based on
prognostic factors) prognostic factors) prognostic factors)
Saskatchewan Open Restricted Restricted Restricted
Manitoba Open Open Open Open
(after deductible (after deductible (after deductible
is met) is met) is met)
Atlantic Canada Open Restricted Restricted Restricted
(Newfoundland and Labrador,
Prince Edward Island,
New Brunswick)
Nova Scotia Open Open Open OpenVERMA et al.
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Provincially centralized care can offer great benefits
if guidelines favour a new anticancer agent for in-
corporation into therapeutic regimens, but can also
create a serious impediment for new treatments if
delays occur in the writing of guidelines or in formu-
lary listing.
In Quebec, for instance, where no standardized pro-
vincial clinical guidelines are in place, a Pharmacol-
ogy Advisory Council recommends provincial
formulary listing, but oncologists and pharmacists can
drive the creation of formulary packages as needed.
And although the Comité d’évolution des pratiques en
oncology and the PGTM, a professional body of the four
academic pharmacies (University of Quebec, University
of Sherbrooke, McGill University, and the University
of Montreal), offer drug advice and recommendations,
individual hospitals make the final funding decisions.
It is heartening to note, however, that AIs are now fully
approved and funded provincially. In Ontario, on the
other hand, a Policy Advisory Committee provides
Cancer Care Ontario with the recommended eligibil-
ity criteria for funding under the New Drug Funding
Program after a comprehensive review of disease in-
formation with treatment recommendations, advanced
clinical trial and pharmacoeconomic data, and manu-
facturer details. In fact, Ontario has extensive private
pay options with individuals and their insurers footing
the bill. On the other hand, the Atlantic provinces de-
pend heavily on compassionate drug release by phar-
maceutical manufacturers.
Indeed, the trend toward the private payment op-
tion for cancer drugs is increasing within the public
health system in Saskatchewan, Ontario, New
Brunswick, Nova Scotia, and British Columbia (a pro-
gram in Alberta is ongoing). The financial risks and
uncertainties involved in self-payment for expensive
cancer drugs notwithstanding, third-party insurance
plans and their inadequacies could create a major new
challenge for the Canadian health care system.
Provinces such as Saskatchewan have no formu-
lary listing for oncology products. Most private plans
follow the Saskatchewan Prescription Drug Plan and
therefore do not cover AIs. However, full funding is
available through the Saskatchewan Cancer Agency
following requests from oncologists to the Provin-
cial Oncology Drug Approval Committee on a case-
by-case basis 33. In any case, as at December 2006,
AIs were still not approved for public funding. Ac-
cess to AIs is currently limited to private payers—
self-pay, third-party insurer, or manufacturer’s
compassionate release program—although the drugs
are still administered by public cancer centres or hos-
pitals (Table VII) 34.
Oncologists in Manitoba follow the National
Cancer Institute guidelines or other provincial (Brit-
ish Columbia or Ontario) recommendations. Cancer
Care Manitoba (CCMB) launched the Clinical Practice
Guidelines Initiative in January 2006 to develop evi-
dence-based guidelines for local cancer care prac-
tice. The CCMB recommends funding based on a
review of clinical data and outcomes by a multi-
disciplinary tumour committee 35. Currently, AIs are
fully funded provincially in Manitoba (Table VII).
The Alberta Cancer Board’s Pharmacy and Thera-
peutics Committee considers oncologists’ requests to
have a drug or treatment reviewed by a tumour group
TABLE VII Aromatase inhibitor access and funding by drug and province, as at December 2006 34
Anastrozole (Arimidex a) Letrozole (Femara b) Exemestane (Aromasin c)
Access C, S C, S C, S
British Columbia A A A
Alberta A A A
Saskatchewan N, R, L4 N, R, L4 N, R, L4
Manitoba A A A
Ontario L2, L4 L2, L4 L2, L4
Quebec A A A
New Brunswick C, L2, L4 C, L2, L4 C, L2, L4
Prince Edward Island N, C N, C N, C
Nova Scotia L2, L4 L2, L4 N
Newfoundland and
Labrador C, L1, L2 C, L1, L2 C, L1, L2
a AstraZeneca Canada, Mississauga, ON.
b Novartis Pharmaceuticals Canada, Dorval, QC.
c Pfizer Canada, Kirkland, QC.
C = compassionate release from pharmaceutical company; S = self-pay or third-party insurer, drug readily available through retail pharma-
cies; A = approved and fully funded provincially; N = not approved or funded in that province; R = recommended for funding, but not yet
approved, still pending; L1 = limited access on a case-to-case basis (disease-specific factors); L2 = limited access based on coverage for
specific patient groups only (patients over 65 years of age, or those receiving social assistance or welfare); L4 = limited access based on
private payment of the drug (self-pay, third-party insurer, or manufacturer’s compassionate program), but drug administered by public
cancer centre or hospital.CANCER THERAPY DISPARITY
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for development of provincial consensus guidelines
and formulary listing under the Alberta Cancer Board
Outpatient Cancer Drug Benefit Program. In a change
over the 2005 status, the AIs anastrozole, letrozole,
and exemestane were approved for funding in 2006,
with preferred agents to be used at selected time points
in the course of therapy per the available clinical trial
evidence (Table VII).
The British Columbia Cancer Agency (BCCA) re-
imburses approved and indicated drugs for active can-
cer, without any ceiling on patient coverage, but within
budgetary limits. Any new drug must be submitted to
an appropriate BCCA tumour group for approval and
for further evaluation by various expert committees
before it can be requested for inclusion under the BCCA
budget by the province’s Ministry of Health 36. How-
ever, payment in British Columbia for AIs is based on
prognostic factors. Upfront therapy with an AI is rec-
ommended for women with an elevated risk of early
relapse, defined as high grade or low estrogen-recep-
tor (1+) disease, or stage III disease (including any
N2/N3, T4, or T3N+), and excluding women with low-
grade T1N0 tumours. Sequential therapy is preferred
for most postmenopausal women who are not at high
risk for early relapse. Currently, all three of the AIs
are fully funded provincially for any of the time points
in the adjuvant setting.
In Atlantic Canada outside of Nova Scotia, pub-
lic funding of AIs is restricted and extremely fragile,
available only as second-line therapy for patients
who have failed, are intolerant of, or have an abso-
lute contraindication to tamoxifen. Submissions are
considered based on health economic analysis and
safety and efficacy data, although instances of com-
passionate release by the drug manufacturers are
known. None of these provinces has any public fund-
ing program for AIs. As in Ontario, patients in New
Brunswick and Nova Scotia who are over 65 years
of age or are under a social assistance program or
private reimbursement can access AIs. In Prince Ed-
ward Island, none of the AIs has been funded. In
Newfoundland and Labrador, access to AIs is lim-
ited to patients 65 years of age and older, and to
patients with disease-specific factors who are receiv-
ing social assistance and welfare (however, similar
relative risk reductions have been shown for patients
with breast cancer without these disease-specific
factors).
5.2 Trends and Implications
In general, the disparity in funding and access to can-
cer drugs is quite remarkable across Canada and is
not limited to AIs alone. The western provinces, which
have more integrated oncology drug budgets for both
parenteral and oral drugs, have more uniform access
to cancer drugs than do provinces with multiple drug-
funding programs. The four western provinces of
British Columbia, Alberta, Saskatchewan, and
Manitoba have the fewest restrictions in terms of ac-
cess to cancer drugs 34. As at December 31, 2006,
the four western provinces approved and funded 63
cancer drugs as compared with only 45 in the rest of
Canada, which has possible implications for cancer-
specific outcomes across the country. As an example,
the provinces of New Brunswick, Nova Scotia, and
Newfoundland and Labrador have limited access to
the third-generation AIs, and patients in Prince Ed-
ward Island have no access at all and depend entirely
on compassionate release of the drugs by the manu-
facturer 34.
6. CONCLUSION
In summary, provincial treatment guidelines with re-
gard to AIs vary widely (Table V), with Quebec and
Prince Edward Island having no specific guidelines
at all. Public-sector reimbursement in Canada for
adjuvant  AI therapy, unlike that for tamoxifen, is lim-
ited or restricted, although third-party insurance is
available in most provinces. Table VII summarizes
the accessibility to AI endocrine therapies and fund-
ing across Canada as at December 2006 34. A con-
cordance between provinces in funding is needed,
not only for AIs as adjuvant therapy for breast can-
cer, but for all cancer therapies in general. Such a
concordance will pave the way for the development
of uniform national guidelines guaranteeing avail-
ability of prompt and efficacious therapeutic care for
all cancer patients, wherever they reside in Canada.
In addition to evidence-based efficacy and safety
analyses, cost is currently a critical factor in funding
decisions relating to cancer therapeutics. Given these
cost considerations, the need for transparent develop-
ment of appropriate cost-effectiveness models to guide
decision-making at all levels cannot be overstated.
Government, pharmaceutical companies, third-party
payers, self payers, and institutional sources all have
joint responsibility for improving access to useful can-
cer therapeutics, and discussions at all levels should
be undertaken in this regard. Although legislation such
as Ontario’s Transparent Drug System for Patients
Act 37 and formation of the Joint Oncology Drug Re-
view panel are steps in the right direction, the effects
with regard to increasing patient access to evidence-
based therapy have yet to be felt.
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